Latest revenue
$194.5M
as of 2026-03-31
Latest net income
—
as of 2026-03-31
Net margin
—
as of 2026-03-31
Price · 5Y
Live market
delayed ≤15 min- Market cap
- $13.54B
- Enterprise value
- $13.54B
- P/E (trailing)
- —
- Forward P/E
- —
- P/B
- —
- Dividend yield
- 0.0%
- 52-wk high
- $84.94
- 52-wk low
- $31.77
- Beta
- —
- Shares out
- 195.9M
5-year trend
What this company does
Table of Contents BRIDGEBIO PHARMA, INC. Consolidated Statements of Operations (in thousands, except share and per share amounts) Years Ended December 31, 202520242023 Revenues: Net product revenue$362,368 $2,884 $— License and services revenue128,322 218,849 9,303 Royalty revenue11,386 169 — Total revenues, net502,076 221,902 9,303 Operating costs and expenses: Cost of revenues: Cost of goods sold15,687 1,442 — Cost of license, services, and royalty revenue5,275 2,436 2,446 Total cost of revenues20,962 3,878 2,446 Research and development451,953 506,461 455,711 Selling, general and administrative531,225 288,931 150,590 Restructuring, impairment, and related charges21,347 15,605 7,926 Total…
AI summary unavailable — showing raw filing excerpt
Generated from BBIO's filing dated 2026-02-24
Key risks
Table of Contents BRIDGEBIO PHARMA, INC. Consolidated Statements of Comprehensive Loss (in thousands) Years Ended December 31, 202520242023 Net loss$(732,938)$(543,347)$(653,251) Other comprehensive loss: Unrealized gains (losses) on available-for-sale securities4 (23)359 Comprehensive loss(732,934)(543,370)(652,892) Comprehensive loss attributable to redeemable convertible noncontrolling interests and noncontrolling interests8,007 7,585 10,049 Comprehensive loss attributable to common stockholders of BridgeBio$(724,927)$(535,785)$(642,843) The accompanying notes are an integral part of these consolidated financial statements.
AI summary unavailable — showing raw filing excerpt
Generated from BBIO's filing dated 2026-02-24
Profitability
Operating margin
-104.2%
61.0%Net margin
-1.2%
36.6%Return on equity
0.3%
1.0%Return on assets
-0.7%
41.0%Leverage
Debt / equity
-1.45×
10.9%Long-term debt / equity
-0.89×
24.3%Debt / assets
322.9%
24.4%Earnings tracker
| Quarter | Revenue | YoY | Net income | YoY | Net margin |
|---|---|---|---|---|---|
Q1 2026 2026-03-31 | $194.5M | +66.8% | — | — | — |
Q4 2025 2025-12-31 | $154.2M | +2521.2% | — | — | — |
Q3 2025 2025-09-30 | $120.7M | +4318.0% | — | — | — |
Q2 2025 2025-06-30 | $110.6M | +4999.9% | — | — | — |
Q1 2025 2025-03-31 | $116.6M | -44.8% | — | — | — |
Q4 2024 2024-12-31 | $5.9M | — | — | — | — |
Q3 2024 2024-09-30 | $2.7M | -33.2% | — | — | — |
Q2 2024 2024-06-30 | $2.2M | +32.1% | — | — | — |
Year-over-year change vs the same fiscal quarter one year prior. Revenue + net income sourced from SEC 10-Q / 10-K filings — no analyst-consensus dependency.
Industry trend
Pharmaceutical Preparations · SIC 2834
Your notes
Keep private notes on BBIO — thesis, target price, catalysts to watch.
Visible only to you. Never shared. Never used to train AI.
Insider activity
Insider buying
$0
Insider selling
$277.2M
Net activity
−$277.2M
Distinct insiders
11
Open-market trades over the last 365 days.
Recent transactions
Source: SEC Form 4 filings. Officers, directors, and 10%+ owners must disclose share transactions within two business days. RSU grants and tax-withholding rows are excluded by default — compensation activity is not a trading signal.
Who owns BBIO
Institutional value
$5.19B
Total shares held
71.9M
Distinct holders
272
-94 vs prior
As of
2026-03-31
Prior: 2025-12-31
Filers with $100M+ AUM disclose holdings 45 days after quarter end.
Top institutional holders
| # | Manager | Shares | Value | QoQ change | Action |
|---|---|---|---|---|---|
| 1 | BlackRock, Inc. | 14.2M | $1.06B | -341.8K (-2.3%) | Trimmed |
| 2 | VANGUARD PORTFOLIO MANAGEMENT LLC | 8.1M | $600.1M | — | New |
| 3 | VANGUARD CAPITAL MANAGEMENT LLC | 7.8M | $576.2M | — | New |
| 4 | Aisling Capital Management LP | 5.1M | $378.0M | +0 (+0.0%) | No change |
| 5 | Invesco Ltd. | 4.6M | $341.1M | -238.5K (-4.9%) | Trimmed |
| 6 | FRANKLIN RESOURCES INC | 2.4M | $181.1M | +274.0K (+12.7%) | Added |
| 7 | UBS Group AG | 2.0M | $150.5M | +151.2K (+8.1%) | Added |
| 8 | JANE STREET GROUP, LLC | 1.8M | $130.5M | +1.4M (+414.2%) | Added |
| 9 | Pictet Asset Management Holding SA | 1.4M | $101.5M | +110.9K (+8.7%) | Added |
| 10 | PRINCIPAL FINANCIAL GROUP INC | 1.3M | $98.8M | +16.1K (+1.2%) | Added |
| 11 | BNP PARIBAS FINANCIAL MARKETS | 1.3M | $97.1M | -285.5K (-17.9%) | Trimmed |
| 12 | JPMORGAN CHASE & CO | 1.3M | $91.0M | +453.3K (+52.8%) | Added |
| 13 | VANGUARD FIDUCIARY TRUST CO | 1.2M | $87.3M | — | New |
| 14 | Clearbridge Investments, LLC | 951.2K | $70.6M | +452.9K (+90.9%) | Added |
| 15 | Allspring Global Investments Holdings, LLC | 889.4K | $66.2M | — | New |
| 16 | Ensign Peak Advisors, Inc | 836.6K | $62.1M | -426.9K (-33.8%) | Trimmed |
| 17 | Capital Research Global Investors | 763.7K | $56.7M | -1.2M (-60.5%) | Trimmed |
| 18 | CITIGROUP INC | 746.5K | $55.4M | +46.2K (+6.6%) | Added |
| 19 | FEDERATED HERMES, INC. | 588.4K | $43.7M | +1.6K (+0.3%) | Added |
| 20 | Bank of New York Mellon Corp | 577.3K | $42.9M | -19.1K (-3.2%) | Trimmed |
Source: SEC Form 13F-HR. Positions aggregated across sub-managers within each firm. Options (puts/calls) excluded — common stock only.
Top questions investors are asking
Coming once BBIO's latest filing finishes processing.